| Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 18 (4), 452-478, 2020 | 845 | 2020 |
| The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy Z Mitri, T Constantine, R O′ Regan Chemotherapy research and practice 2012 (1), 743193, 2012 | 745 | 2012 |
| Emerging use of nanoparticles in diagnosis and treatment of breast cancer MV Yezhelyev, X Gao, Y Xing, A Al-Hajj, S Nie, RM O'Regan The lancet oncology 7 (8), 657-667, 2006 | 735 | 2006 |
| Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry Y Xing, Q Chaudry, C Shen, KY Kong, HE Zhau, LW Chung, JA Petros, ... Nature protocols 2 (5), 1152-1165, 2007 | 666 | 2007 |
| The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers E Paplomata, R O’Regan Therapeutic advances in medical oncology 6 (4), 154-166, 2014 | 606 | 2014 |
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial F André, R O'Regan, M Ozguroglu, M Toi, B Xu, G Jerusalem, N Masuda, ... The lancet oncology 15 (6), 580-591, 2014 | 585 | 2014 |
| Triple-negative breast cancer in African-American women: disparities versus biology EC Dietze, C Sistrunk, G Miranda-Carboni, R O'regan, VL Seewaldt Nature Reviews Cancer 15 (4), 248-254, 2015 | 526 | 2015 |
| Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA MJ Lund, KF Trivers, PL Porter, RJ Coates, B Leyland-Jones, OW Brawley, ... Breast cancer research and treatment 113, 357-370, 2009 | 517 | 2009 |
| Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer X Li, J Yang, L Peng, AA Sahin, L Huo, KC Ward, R O’Regan, MA Torres, ... Breast cancer research and treatment 161, 279-287, 2017 | 503 | 2017 |
| Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging MV Yezhelyev, L Qi, RM O’Regan, S Nie, X Gao Journal of the American Chemical Society 130 (28), 9006-9012, 2008 | 491 | 2008 |
| NCCN guidelines insights: breast cancer, version 1.2017 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the national comprehensive cancer network 15 (4), 433-451, 2017 | 488 | 2017 |
| Insulin-like growth factor-I–dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells TR Graham, HE Zhau, VA Odero-Marah, AO Osunkoya, KS Kimbro, ... Cancer research 68 (7), 2479-2488, 2008 | 471 | 2008 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 452 | 2020 |
| Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 16 (3), 310-320, 2018 | 440 | 2018 |
| Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a … A Di Leo, S Johnston, KS Lee, E Ciruelos, PE Lønning, W Janni, ... The Lancet Oncology 19 (1), 87-100, 2018 | 398 | 2018 |
| Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation O Seleverstov, O Zabirnyk, M Zscharnack, L Bulavina, M Nowicki, ... Nano letters 6 (12), 2826-2832, 2006 | 292 | 2006 |
| NCCN guidelines® insights: Breast cancer, version 4.2021: Featured updates to the NCCN guidelines WJ Gradishar, MS Moran, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 19 (5), 484-493, 2021 | 286 | 2021 |
| In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots MV Yezhelyev, A Al-Hajj, C Morris, AI Marcus, T Liu, M Lewis, C Cohen, ... ADVANCED MATERIALS-DEERFIELD BEACH THEN WEINHEIM- 19 (20), 3146, 2007 | 272 | 2007 |
| Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab F Andre, M Campone, R O'Regan, C Manlius, C Massacesi, S Tarek, ... Journal of Clinical Oncology 28 (34), 5110-5115, 2010 | 245 | 2010 |
| Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice K Yao, ES Lee, DJ Bentrem, G England, JIMG Schafer, RM O’Regan, ... Clinical Cancer Research 6 (5), 2028-2036, 2000 | 245 | 2000 |